Blood Clots And Erythrocytosis
ironjustice
I say it is the erythrocytosis which leads to thromboembolism the SAME
erythrocytyosis which causes one to die when flying .. blood clot.
One way to test this would be to give a drug to people which increases
their red blood cells and see if they .. die ..
They .. doooo ..
http://www.medscape.com/viewarticle/712143
From Medscape Medical News
Sleep Apnea a Risk Factor for Venous Thromboembolism
Kristina Rebelo
November 11, 2009 (San Diego, California) — Sleep-disordered breathing
(SDB) is a condition rife with significant risk factors for blood clot
events that should be identified in the clinical setting, according to
the findings of a large retrospective study, presented here at CHEST
2009: American College of Chest Physicians Annual Meeting.
Intermittent hypoxia and hypercapnia have been associated with adverse
cardiovascular outcomes, but this study found an association with
venous thromboembolism (VTE) — either pulmonary embolism (PE) or deep
vein thrombosis (DVT).
---------------------
Drugs to treat anemia in cancer patients linked to thromboembolism
Published: Tuesday, November 10, 2009 - 17:46 in Health & Medicine
Medications frequently given to cancer patients to reduce their risk
of anemia are associated with an increased risk of deep vein
thrombosis or pulmonary embolism, according to new research led by
Dawn Hershman, M.D, M.S., co-director of the breast cancer program at
the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian
Hospital/Columbia University Medical Center. The findings will be
published online on Nov. 10, 2009 in the Journal of the National
Cancer Institute (ahead of the Dec. 2, 2009 print edition). The anemia-
reducing medications, known as erythropoiesis-stimulating agents
(i.e., erythropoietin and darbopoietin) or ESAs, stimulate red blood
cell production and are intended to reduce the number of blood
transfusions required during chemotherapy. However, concerns about the
risks of deep vein thrombosis or pulmonary embolism (manifestations of
venous thromboembolism) and mortality exist.
"This research answers important questions about outcomes of ESAs when
used in long-term clinical practice with oncology patients," said Dr.
Hershman, the Florence Irving Assistant Professor of Medicine and
Epidemiology at Columbia University Medical Center, whose research is
dedicated to examining cancer survivorship. "While ESAs were given to
reduce the need for blood transfusions, a substantial reduction in the
use of blood transfusions was not observed. However, an increase risk
of deep vein thrombosis or pulmonary embolism was confirmed."
"This analysis confirms the association between ESAs and venous
thromboembolism, which was observed in previous meta-analysis," said
Dr. Hershman. "This new finding is significant because where the meta-
analysis looked at pooled data from randomized clinical trials, this
data is from community practice – real-life clinical settings – where
you can often see things that wouldn't necessarily show-up in a short-
term, 12-week study. Additionally, this analysis included data from
more than 50,000 patients– including those with more advanced cancer
or high-risk status, who therefore might not have been candidates for
clinical trials."
Based on previous findings, in the spring of 2007, the FDA required a
black-box warning on ESAs about the potential for venous
thromboembolism, tumor promotion, and decreased survival in ESA users.
The warning suggested limiting the use of ESAs to specific tumor
types, durations, doses, and targeted hemoglobin levels. In addition,
the Center for Medicare and Medicaid Services proposed eliminating or
limiting coverage for ESAs as treatment for some cancers.
"But what is reassuring about our findings are that they don't show an
increased risk of mortality when ESAs are given with chemotherapy,"
said Dr. Hershman.
Dr. Hershman and colleagues analyzed the association between use of
ESAs and venous thromboembolism and overall survival in patients who
were 65 years or older and diagnosed with colon, non-small cell lung,
or breast cancer or diffuse large B-cell lymphoma, between 1991-2002.
These cancers were chosen because they were thought to be common
cancers for which ESAs were frequently used. Patients were identified
in the Surveillance, Epidemiology, and End Results–Medicare database,
which at the time contained records of patients diagnosed with cancer
in regions that represented approximately 14 percent of the U.S.
population.
Results demonstrated that more patients who received an ESA developed
deep vein thrombosis or pulmonary embolism, as compared to patients
who did not. Overall survival was similar in both groups. The number
of patients receiving ESAs increased approximately 10-fold from 1991
through 2002, with approximately 50 percent of patients with advanced
cancer undergoing chemotherapy receiving ESAs by 2002. The rate of
blood transfusion per year during the same time period, however,
remained constant at 22 percent.
"Further efforts at monitoring use and long-term toxicity of expensive
oncology drugs should be put in place to ensure that for any drug the
benefits outweigh the risks in community practice," the authors write
in the paper.
In the JNCI paper, the authors note that ESAs may be of particular
interest from a public policy perspective because of the costs
associated with their use. Total U.S. sales of ESAs were $10 billion
in 2006, accounting for a greater Medicare Part B expenditure than any
other drug.
Source: Columbia University Medical Center
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh
Man Is A Herbivore!
http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk